Moreover, recent studies revealed that pharmacologic and genetic inhibition of ERK5 signaling compromises cancer stem cell (CSC) phenotypes in leukemia and colon cancer (20, 21), although the effects of ERK5 inhibition were not tested in vivo. This evidence concerns the gene MAPK7 and malignant colon neoplasm.